Found: 96
Select item for more details and to access through your institution.
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 2, p. 338, doi. 10.1002/ajh.26788
- By:
- Publication type:
- Article
Cell‐free DNA analysis for detection of MYD88<sup>L265P</sup> and CXCR4<sup>S338X</sup> mutations in Waldenström macroglobulinemia.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 7, p. E250, doi. 10.1002/ajh.26184
- By:
- Publication type:
- Article
CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 4, p. E95, doi. 10.1002/ajh.25730
- By:
- Publication type:
- Article
Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemia.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 4, p. 372, doi. 10.1002/ajh.25712
- By:
- Publication type:
- Article
Spotting the elusive Siberian tiger: Complete response to ibrutinib in a patient with Waldenström macroglobulinemia.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 8, p. E201, doi. 10.1002/ajh.25142
- By:
- Publication type:
- Article
Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 4, p. 511, doi. 10.1002/ajh.25023
- By:
- Publication type:
- Article
Comparing apples to oranges: A commentary on the Mayo study of MYD88 significance in Waldenstrom's macroglobulinemia.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 3, p. E69, doi. 10.1002/ajh.24997
- By:
- Publication type:
- Article
Histological transformation to diffuse large B-cell lymphoma in patients with Waldenström macroglobulinemia.
- Published in:
- American Journal of Hematology, 2016, v. 91, n. 10, p. 1032, doi. 10.1002/ajh.24477
- By:
- Publication type:
- Article
Atrial fibrillation associated with ibrutinib in Waldenström macroglobulinemia.
- Published in:
- American Journal of Hematology, 2016, v. 91, n. 6, p. E312, doi. 10.1002/ajh.24366
- By:
- Publication type:
- Article
Survival outcomes of secondary cancers in patients with waldenström macroglobulinemia: An analysis of the SEER database.
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 8, p. 696, doi. 10.1002/ajh.24052
- By:
- Publication type:
- Article
Cyclophosphamide, bortezomib, and dexamethasone combination in waldenstrom macroglobulinemia.
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 6, p. E122, doi. 10.1002/ajh.23985
- By:
- Publication type:
- Article
Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia.
- Published in:
- American Journal of Hematology, 2014, v. 89, n. 3, p. 237, doi. 10.1002/ajh.23620
- By:
- Publication type:
- Article
Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia.
- Published in:
- American Journal of Hematology, 2010, v. 85, n. 9, p. 670, doi. 10.1002/ajh.21788
- By:
- Publication type:
- Article
Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia.
- Published in:
- American Journal of Hematology, 2007, v. 82, n. 1, p. 83, doi. 10.1002/ajh.20724
- By:
- Publication type:
- Article
IgM-Related Immunoglobulin Light Chain (AL) Amyloidosis.
- Published in:
- Hemato, 2022, v. 3, n. 4, p. 731, doi. 10.3390/hemato3040049
- By:
- Publication type:
- Article
Activation of NF-KB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.
- Published in:
- Oncogene, 2002, v. 21, n. 37, p. 5673, doi. 10.1038/sj.onc.1205664
- By:
- Publication type:
- Article
Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia.
- Published in:
- PLoS ONE, 2018, v. 13, n. 10, p. 1, doi. 10.1371/journal.pone.0204589
- By:
- Publication type:
- Article
Ophthalmologic Techniques to Assess the Severity of Hyperviscosity Syndrome and the Effect of Plasmapheresis in Patients with Waldenström's Macroglobulinemia.
- Published in:
- Clinical Lymphoma & Myeloma, 2009, v. 9, n. 1, p. 100
- By:
- Publication type:
- Article
Soluble CD27 Is a Faithful Marker of Disease Burden and Is Unaffected by the Rituximab-Induced IgM Flare, as Well as by Plasmapheresis, in Patients with Waldenström's Macroglobulinemia.
- Published in:
- Clinical Lymphoma & Myeloma, 2009, v. 9, n. 1, p. 56
- By:
- Publication type:
- Article
Advances in the Biology and Treatment of Waldenström's Macroglobulinemia: A Report from the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden.
- Published in:
- Clinical Lymphoma & Myeloma, 2009, v. 9, n. 1, p. 10
- By:
- Publication type:
- Article
Balancing Risk Versus Benefit in the Treatment of Waldenström's Macroglobulinemia Patients with Nucleoside Analogue–Based Therapy.
- Published in:
- Clinical Lymphoma & Myeloma, 2009, v. 9, n. 1, p. 71
- By:
- Publication type:
- Article
Comparative Outcomes Following CP-R, CVP-R, and CHOP-R in Waldenström's Macroglobulinemia.
- Published in:
- Clinical Lymphoma & Myeloma, 2009, v. 9, n. 1, p. 62
- By:
- Publication type:
- Article
Novel Agents in the Treatment of Waldenström's Macroglobulinemia.
- Published in:
- Clinical Lymphoma & Myeloma, 2007, v. 7, p. S199
- By:
- Publication type:
- Article
Genetic Linkage of FcgγRIIa and FcγRIIIa and Implications for Their Use in Predicting Clinical Responses to CD20-Directed Monoclonal Antibody Therapy.
- Published in:
- Clinical Lymphoma & Myeloma, 2007, v. 7, n. 4, p. 286
- By:
- Publication type:
- Article
CD52 Is Expressed on Human Mast Cells and Is a Potential Therapeutic Target in Waldenström's Macroglobulinemia and Mast Cell Disorders.
- Published in:
- Clinical Lymphoma & Myeloma, 2006, v. 6, n. 6, p. 478
- By:
- Publication type:
- Article
Update on Recommendations for Assessing Response from the Third International Workshop on Waldenström's Macroglobulinemia.
- Published in:
- Clinical Lymphoma & Myeloma, 2006, v. 6, n. 5, p. 380, doi. 10.3816/clm.2006.n.013
- By:
- Publication type:
- Article
Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias.
- Published in:
- Biologics: Targets & Therapy, 2008, v. 2, n. 3, p. 419
- By:
- Publication type:
- Article
Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE Study.
- Published in:
- Open Forum Infectious Diseases, 2022, v. 9, n. 5, p. 1, doi. 10.1093/ofid/ofac104
- By:
- Publication type:
- Article
SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 8, p. 547, doi. 10.1016/j.clml.2022.02.005
- By:
- Publication type:
- Article
OAB-045: COVID-19 vaccine responsiveness in patients with Multiple Myeloma and Waldenström Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S29, doi. 10.1016/S2152-2650(21)02119-4
- By:
- Publication type:
- Article
OAB-040: Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S26, doi. 10.1016/S2152-2650(21)02114-5
- By:
- Publication type:
- Article
Ibrutinib/Rituximab versus Placebo/Rituximab: A Randomized, Phase 3 Trial in Waldenström's Macroglobulinemia (iNNOVATE).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S283, doi. 10.1016/j.clml.2018.07.217
- By:
- Publication type:
- Article
Comparative Response Assessment by Serum Immunoglobulin M M-Protein and Total Serum Immunoglobulin M After Treatment of Patients With Waldenström Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2013, v. 13, n. 2, p. 250, doi. 10.1016/j.clml.2013.04.002
- By:
- Publication type:
- Article
Proceedings of the Seventh International Workshop on Waldenström Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2013, v. 13, n. 2, p. 181, doi. 10.1016/j.clml.2013.04.001
- By:
- Publication type:
- Article
Challenges With Serum Protein Electrophoresis in Assessing Progression and Clinical Response in Patients With Waldenström Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2013, v. 13, n. 2, p. 247, doi. 10.1016/j.clml.2013.03.001
- By:
- Publication type:
- Article
Patients With Waldenström Macroglobulinemia Commonly Present With Iron Deficiency and Those With Severely Depressed Transferrin Saturation Levels Show Response to Parenteral Iron Administration.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2013, v. 13, n. 2, p. 241, doi. 10.1016/j.clml.2013.02.016
- By:
- Publication type:
- Article
microRNA Aberrations in Waldenström Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2013, v. 13, n. 2, p. 205, doi. 10.1016/j.clml.2013.02.007
- By:
- Publication type:
- Article
Familial Disease Predisposition Impacts Treatment Outcome in Patients With Waldenström Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2012, v. 12, n. 6, p. 433, doi. 10.1016/j.clml.2012.08.006
- By:
- Publication type:
- Article
Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen.
- Published in:
- British Journal of Haematology, 2011, v. 154, n. 3, p. 357, doi. 10.1111/j.1365-2141.2011.08750.x
- By:
- Publication type:
- Article
Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia.
- Published in:
- British Journal of Haematology, 2011, v. 154, n. 2, p. 223, doi. 10.1111/j.1365-2141.2011.08726.x
- By:
- Publication type:
- Article
Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia.
- Published in:
- British Journal of Haematology, 2009, v. 145, n. 1, p. 59, doi. 10.1111/j.1365-2141.2009.07592.x
- By:
- Publication type:
- Article
The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia.
- Published in:
- British Journal of Haematology, 2008, v. 142, n. 5, p. 775, doi. 10.1111/j.1365-2141.2008.07257.x
- By:
- Publication type:
- Article
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.
- Published in:
- British Journal of Haematology, 2005, v. 128, n. 2, p. 192, doi. 10.1111/j.1365-2141.2004.05286.x
- By:
- Publication type:
- Article
research paper Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma.
- Published in:
- British Journal of Haematology, 2004, v. 125, n. 3, p. 343, doi. 10.1111/j.1365-2141.2004.04929.x
- By:
- Publication type:
- Article
Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells.
- Published in:
- British Journal of Haematology, 2003, v. 121, n. 4, p. 592, doi. 10.1046/j.1365-2141.2003.04322.x
- By:
- Publication type:
- Article
A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib.
- Published in:
- EJHaem, 2022, v. 3, n. 3, p. 927, doi. 10.1002/jha2.493
- By:
- Publication type:
- Article
Evolution of Management and Outcomes in Waldenstrom Macroglobulinemia: A Population-Based Analysis.
- Published in:
- Oncologist, 2016, v. 21, n. 11, p. 1377, doi. 10.1634/theoncologist.2016-0126
- By:
- Publication type:
- Article
Clinical relevance of soluble HLA class I molecules in Waldenstrom Macroglobulinemia.
- Published in:
- European Journal of Haematology, 2008, v. 80, n. 6, p. 503, doi. 10.1111/j.1600-0609.2008.01060.x
- By:
- Publication type:
- Article
Infectious Complications Associated with Alemtuzumab Use for Lymphoproliferative Disorders.
- Published in:
- Clinical Infectious Diseases, 2006, v. 43, n. 1, p. 16, doi. 10.1086/504811
- By:
- Publication type:
- Article
Dose reductions in patients with Waldenström macroglobulinaemia treated with ibrutinib.
- Published in:
- British Journal of Haematology, 2023, v. 201, n. 5, p. 897, doi. 10.1111/bjh.18643
- By:
- Publication type:
- Article